Drug Profile
Regadenoson - Astellas Pharma/Rapidscan Pharma Solutions/Gilead Sciences
Alternative Names: CVT 3146; Lexiscan; RapiscanLatest Information Update: 04 Nov 2018
Price :
$50
*
At a glance
- Originator CV Therapeutics
- Developer Astellas Pharma; Gilead Sciences; National Jewish Health; Rapidscan Pharma Solutions
- Class Imaging agents; Purines; Pyrazoles; Small molecules; Vasodilators
- Mechanism of Action Adenosine A2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Coronary disorders
- No development reported Pulmonary hypertension
Most Recent Events
- 24 Jun 2018 Biomarkers information updated
- 14 Jun 2018 Medical University of South Carolina and Astellas Pharma completes a phase II trial in Coronary disorders (Diagnosis) in USA (NCT03103061)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Pulmonary-hypertension in USA (IV, Injection)